Injectables & Drug Delivery Forum 2026

Injectable drug delivery is a cornerstone of modern medicine, enabling rapid and precise administration of therapies, especially for biologics, vaccines, and chronic disease management. Globally, the market is highly advanced and rapidly expanding—valued at $633.77 billion in 2024, rising to $690.23 billion in 2025, and projected to reach $1,034.78 billion by 2030 at a strong CAGR of 8.4%. This growth is fueled by innovations such as autoinjectors, prefilled syringes, wearable injectors, and connected delivery technologies, supported by robust regulatory frameworks and high patient adoption of self-administration.

In contrast, the Indian injectable market, though smaller in scale, is growing quickly, driven by rising biologics and biosimilar use, increased vaccination needs, and a strong presence in generic sterile manufacturing. India remains a global hub for cost-effective injectable production, with dominant use of vials, ampoules, and traditional delivery formats, while advanced devices like autoinjectors and microneedles are gradually gaining traction. Although regulatory alignment and device innovation are still evolving, India’s expanding healthcare demand and manufacturing capabilities are positioning it as an increasingly influential player in the global injectable ecosystem.